AKT1 and cancer: PI3K-AKT-MTOR inhibitors developed to treat cancer potentially represent novel anti-seizure therapeutics (Maira et al., 2012; Cardamone et al., 2014; Lindhurst et al., 2015; Venot et al., 2018; Zou et al., 2020; Forde et al., 2021).